Retroperitoneal Fibrosis: Clinical Trials

16 trials for Retroperitoneal Fibrosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 4 recruiting, 4 unknown, 1 active not recruiting. 5 Phase 4, 3 Phase 2, 2 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 45Completed 2, Unknown 2, Recruiting 1
Phase 23Completed 2, Unknown 1
Phase 12Completed 2
Phase 32Completed 1, Unknown 1

Follow Retroperitoneal Fibrosis: new trials by email Literature Review of Retroperitoneal Fibrosis trials Research Report on Retroperitoneal Fibrosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Distinguishing Retroperitoneal Fibrosis and Sarcoma from Other Retroperitoneal Diseases Via Radiomics
Radiomics Algortihm - Retroperitoneal Sarcoma, Retroperitoneal Fibrosis
Active not recruitingHeidelberg University6002023-11-012024-12-19
Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis
Prednisone - Idiopathic Retroperitoneal Fibrosis
Phase 4RecruitingAssistance Publique - Hôpitaux de Paris412022-11-252025-05-25
Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis
Tocilizumab monotherapy - Chronic Periaortitis, Tocilizumab Monotherapy
CompletedPeking Union Medical College Hospital122020-07-152023-03-02
A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis
Tocilizumab, Glucocorticoids - Idiopathic Retroperitoneal Fibrosis
Phase 4UnknownPeking Union Medical College Hospital402020-07-012021-03-22
National Registry of IRPF in China
Idiopathic Retroperitoneal Fibrosis
RecruitingPeking Union Medical College Hospital5002020-03-172020-03-19
A Prospective Cohort Study of IRPF in China
Idiopathic Retroperitoneal Fibrosis
RecruitingPeking Union Medical College Hospital5002020-01-172020-03-18
A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis
Cyclophosphamide and glucocorticoids, Glucocorticoids - Idiopathic Retroperitoneal Fibrosis
Phase 4UnknownPeking Union Medical College Hospital402020-01-032021-03-19
Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
Sirolimus, Corticosteroid - Retroperitoneal Fibrosis
Phase 2 / Phase 3CompletedPeking University International Hospital642018-07-012026-09-22
Treatment of IgG4-Related Disease With Revlimid and Rituximab
Rituximab, Lenalidomide - Immunoglobulin G Subclass 4 Related Disease, IgG4-related Disease
Phase 1CompletedMayo Clinic62016-04-012019-07-08
Leflunomide for Maintenance of Remission in IgG4 Related Disease
Prednisone, Leflunomide - Immunoglobulin G4 Related Sclerosing Disease
Phase 4CompletedChinese PLA General Hospital682016-03-012019-03-06
Atorvastatin as an Adjunct to DFDBA in Intrabony Defects
DFDBA, DFDBA with atorvastatin - Chronic Periaortitis, Intrabony Periodontal Defect
Phase 4CompletedKamineni Institute of Dental Sciences262013-04-012017-01-04
Rituximab in IgG4-RD: A Phase 1-2 Trial
Rituximab - Retroperitoneal Fibrosis, Autoimmune Pancreatitis
Phase 1 / Phase 2CompletedMassachusetts General Hospital302012-04-012017-07-02
Aortitis and Retroperitoneal Fibrosis: Evaluation of Diagnostic Criteria
Establish the clinical, biological and radiological characteristics of patients - Idiopathic Aortitis, Retroperitoneal Fibrosis
CompletedCentre Hospitalier Universitaire, Amiens2102010-09-242026-06-12
National Registry of Rare Kidney Diseases
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
RecruitingUK Kidney Association350002009-11-062023-10-04
Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial
Methotrexate+Prednisone, Prednisone - Idiopathic Retroperitoneal Fibrosis, Perianeurysmal Retroperitoneal Fibrosis
Phase 3UnknownUniversity of Parma2002007-05-012010-11-15
Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis
Tamoxifen, Prednisone - Retroperitoneal Fibrosis
Phase 2UnknownUniversity of Parma382000-10-012007-02-27

Narrower conditions

Autoimmune Pancreatitis (2)  ·  Immunoglobulin G4-Related Disease (2)  ·  Lymphadenopathy (2)  ·  Adenine phosphoribosyltransferase deficiency (1)  ·  Atypical Hemolytic Uremic Syndrome (1)  ·  Bartter Syndrome (1)  ·  Calciphylaxis (1)  ·  Chronic Periodontitis (1)  ·  Cystinosis (1)  ·  Cystinuria (1)  ·  Dent Disease (1)  ·  Denys-Drash Syndrome (1)  ·  Diabetes Insipidus, Nephrogenic (1)  ·  Fabry Disease (1)

Broader conditions

Fibrosis (16)  ·  Pathologic Processes (16)  ·  Pathological Conditions, Signs and Symptoms (16)  ·  Autoimmune Diseases (4)  ·  Disease Attributes (4)  ·  Immune System Diseases (4)  ·  Chronic Disease (3)  ·  Digestive System Diseases (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Mouth Diseases (3)  ·  Pancreatic Diseases (3)  ·  Stomatognathic Diseases (3)  ·  Lymphatic Diseases (2)  ·  Nervous System Diseases (2)  ·  Pancreatitis (2)

Interventions

Prednisone (5)  ·  Glucocorticoids (2)  ·  Rituximab (2)  ·  Adrenal Cortex Hormones (1)  ·  Atorvastatin (1)  ·  Biological Products (1)  ·  Cyclophosphamide (1)  ·  Leflunomide (1)  ·  Lenalidomide (1)  ·  Prednisolone (1)  ·  Sirolimus (1)  ·  Tamoxifen (1)  ·  Transplantation, Homologous (1)  ·  tocilizumab (1)

Sponsors

Peking Union Medical College Hospital (5)  ·  University of Parma (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Centre Hospitalier Universitaire, Amiens (1)  ·  Chinese PLA General Hospital (1)  ·  Heidelberg University (1)  ·  Kamineni Institute of Dental Sciences (1)  ·  Massachusetts General Hospital (1)  ·  Mayo Clinic (1)  ·  Peking University International Hospital (1)  ·  UK Kidney Association (1)

Countries

China (8)  ·  France (2)  ·  Italy (2)  ·  Germany (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Arezou Khosroshahi, MD (1)  ·  Augusto Vaglio, MD, PhD (1)  ·  Carlo Buzio, MD (1)  ·  Etika Rathi, MDS (1)  ·  Hui Gao, Doctor (1)  ·  Jian Zhu (1)  ·  John H Stone, MD, MPH (1)  ·  Mark D Topazian, MD (1)  ·  Wen Zhang, MD (1)

Results publications

PMID 21733570, PMID 25667206, PMID 32113839, PMID 40974866

NIH funding

2008 (1)